MYCN

Summary

Gene Symbol: MYCN
Description: MYCN proto-oncogene, bHLH transcription factor
Alias: MODED, N-myc, NMYC, ODED, bHLHe37, N-myc proto-oncogene protein, class E basic helix-loop-helix protein 37, neuroblastoma MYC oncogene, neuroblastoma-derived v-myc avian myelocytomatosis viral related oncogene, oncogene NMYC, pp65/67, v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog
Species: human

Top Publications

  1. pmc Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas
    Jaime Torres
    Department of Anatomy and Cell Biology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA
    Int J Oncol 37:983-91. 2010
  2. ncbi High mobility group A1 is a molecular target for MYCN in human neuroblastoma
    Giuseppe Giannini
    Department of Experimental Medicine and Pathology, University La Sapienza, Rome, Italy
    Cancer Res 65:8308-16. 2005
  3. pmc Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival
    Isabella Bray
    Department of Cancer Genetics, Royal College of Surgeons in Ireland, Dublin, Ireland
    PLoS ONE 4:e7850. 2009
  4. doi A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF
    Nunzio Iraci
    University of Bologna, Department of Biology, Bologna, Italy
    Cancer Res 71:404-12. 2011
  5. doi N-MYC promotes cell proliferation through a direct transactivation of neuronal leucine-rich repeat protein-1 (NLRR1) gene in neuroblastoma
    M S Hossain
    Division of Biochemistry, Chiba Cancer Center Research Institute, Chiba, Japan
    Oncogene 27:6075-82. 2008
  6. pmc The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma
    Andrew Slack
    Center for Cell and Gene Therapy, Texas Children s Cancer Center, Baylor College of Medicine, 1102 Bates Street, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 102:731-6. 2005
  7. pmc Haplotype association mapping of acute lung injury in mice implicates activin a receptor, type 1
    George D Leikauf
    Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15219 3130, USA
    Am J Respir Crit Care Med 183:1499-509. 2011
  8. pmc N-myc mRNA forms an RNA-RNA duplex with endogenous antisense transcripts
    G W Krystal
    Massey Cancer Center, Division of Hematology Oncology, Medical College of Virginia, Richmond
    Mol Cell Biol 10:4180-91. 1990
  9. ncbi Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage
    G M Brodeur
    Science 224:1121-4. 1984
  10. ncbi Nitric oxide negatively regulates proliferation and promotes neuronal differentiation through N-Myc downregulation
    Elisabetta Ciani
    Department of Human and General Physiology, University of Bologna, Piazza di Porta San Donato 2, 40127, Bologna, Italy
    J Cell Sci 117:4727-37. 2004

Research Grants

  1. N-myc Targeted Therapeutics for Childhood Neuroblastoma
    CATHERINE BURKHART; Fiscal Year: 2007
  2. NF-kappaB N-myc in Oncogenic Pathways of the CNS
    Raquel Sitcheran; Fiscal Year: 2010
  3. ANTIBODIES TO INVESTIGATE AND TREAT NEUROBLASTOMA
    Christopher Frantz; Fiscal Year: 1992
  4. Role of Polyamines in MYCN-Amplified Neuroblastoma
    ANDRE BACHMANN; Fiscal Year: 2009
  5. Genetic Susceptibility Factors in the Etiology of Neuroblastoma
    Andrew Olshan; Fiscal Year: 2012
  6. Development of sd-rxRNAs as Therapy for Retinoblastoma and Other Malignancies
    Pamela Pavco; Fiscal Year: 2012
  7. DANA LYNN TAKEKO KOOMOA; Fiscal Year: 2016
  8. Min Hee Kang; Fiscal Year: 2016
  9. MYCN Function in Neuroblastoma
    Naohiko Ikegaki; Fiscal Year: 2012
  10. Jianhua Yang; Fiscal Year: 2014

Detail Information

Publications225 found, 100 shown here

  1. pmc Biological effects of induced MYCN hyper-expression in MYCN-amplified neuroblastomas
    Jaime Torres
    Department of Anatomy and Cell Biology, College of Medicine, University of Illinois at Chicago, Chicago, IL 60612, USA
    Int J Oncol 37:983-91. 2010
    ..The tumor exhibits two different phenotypes: favorable and unfavorable. MYCN amplification is associated with rapid tumor progression and the worst neuroblastoma disease outcome...
  2. ncbi High mobility group A1 is a molecular target for MYCN in human neuroblastoma
    Giuseppe Giannini
    Department of Experimental Medicine and Pathology, University La Sapienza, Rome, Italy
    Cancer Res 65:8308-16. 2005
    ..On retinoic acid (RA) treatment of MYCN-amplified neuroblastoma cell lines, HMGA1 decreases with a kinetics that strictly follows MYCN repression...
  3. pmc Widespread dysregulation of MiRNAs by MYCN amplification and chromosomal imbalances in neuroblastoma: association of miRNA expression with survival
    Isabella Bray
    Department of Cancer Genetics, Royal College of Surgeons in Ireland, Dublin, Ireland
    PLoS ONE 4:e7850. 2009
    ..Thirty-seven miRNAs were significantly over- or under-expressed in MYCN amplified tumors relative to MYCN single copy tumors, indicating a potential role for the MYCN transcription factor ..
  4. doi A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF
    Nunzio Iraci
    University of Bologna, Department of Biology, Bologna, Italy
    Cancer Res 71:404-12. 2011
    ..Interestingly, TRKA and p75NTR expression is often attenuated in aggressive MYCN-amplified tumors, suggesting a causal link between elevated MYCN activity and the transcriptional repression of ..
  5. doi N-MYC promotes cell proliferation through a direct transactivation of neuronal leucine-rich repeat protein-1 (NLRR1) gene in neuroblastoma
    M S Hossain
    Division of Biochemistry, Chiba Cancer Center Research Institute, Chiba, Japan
    Oncogene 27:6075-82. 2008
    ..Collectively, our present findings provide a novel insight into understanding molecular mechanisms behind aggressive neuroblastoma with N-MYC amplification...
  6. pmc The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma
    Andrew Slack
    Center for Cell and Gene Therapy, Texas Children s Cancer Center, Baylor College of Medicine, 1102 Bates Street, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 102:731-6. 2005
    The MYCN oncogene is the major negative prognostic marker in neuroblastoma with important roles in both the pathogenesis and clinical behavior of this aggressive malignancy...
  7. pmc Haplotype association mapping of acute lung injury in mice implicates activin a receptor, type 1
    George D Leikauf
    Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15219 3130, USA
    Am J Respir Crit Care Med 183:1499-509. 2011
    ..Because acute lung injury is a sporadic disease produced by heterogeneous precipitating factors, previous genetic analyses are mainly limited to candidate gene case-control studies...
  8. pmc N-myc mRNA forms an RNA-RNA duplex with endogenous antisense transcripts
    G W Krystal
    Massey Cancer Center, Division of Hematology Oncology, Medical College of Virginia, Richmond
    Mol Cell Biol 10:4180-91. 1990
    ....
  9. ncbi Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage
    G M Brodeur
    Science 224:1121-4. 1984
    ..Furthermore, N-myc amplification is highly correlated with advanced stages of disease (P less than 0.001) and with the ability to grow in vitro as an established cell line, both of which are associated with a poor prognosis...
  10. ncbi Nitric oxide negatively regulates proliferation and promotes neuronal differentiation through N-Myc downregulation
    Elisabetta Ciani
    Department of Human and General Physiology, University of Bologna, Piazza di Porta San Donato 2, 40127, Bologna, Italy
    J Cell Sci 117:4727-37. 2004
    ....
  11. pmc MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells
    Jung Hee Kang
    Department of Surgery, The University of Texas Medical Branch, Galveston, TX 77555, USA
    Biochem Biophys Res Commun 351:192-7. 2006
    b>MYCN amplification strongly correlates with unfavorable outcomes in patients with neuroblastoma. The aim of this study was to investigate the role of MYCN in neuroblastoma cell differentiation and apoptosis...
  12. ncbi The role of MYCN in the failure of MYCN amplified neuroblastoma cell lines to G1 arrest after DNA damage
    Emma Bell
    Northern Institute for Cancer Research, University of Newcastle upon Tyne, Newcastle upon Tyne, UK
    Cell Cycle 5:2639-47. 2006
    We previously reported that 3 p53 wild type (wt) MYCN amplified (MNA) neuroblastoma cell lines failed to G1 arrest after DNA damage despite induction of p53, p21(WAF1) and MDM2. We hypothesised that this was due to high MYCN expression...
  13. doi Genotype-phenotype correlations in MYCN-related Feingold syndrome
    Carlo L M Marcelis
    Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Hum Mutat 29:1125-32. 2008
    ..FS is caused by germline mutations in or deletions of the MYCN gene...
  14. pmc ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma
    Michael D Hogarty
    Division of Oncology, The Children s Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104 4318, USA
    Cancer Res 68:9735-45. 2008
    Neuroblastoma is a frequently lethal childhood tumor in which MYC gene deregulation, commonly as MYCN amplification, portends poor outcome. Identifying the requisite biopathways downstream of MYC may provide therapeutic opportunities...
  15. pmc miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis
    Li Ma
    Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02142, USA
    Nat Cell Biol 12:247-56. 2010
    ..Expression of miR-9 is activated by MYC and MYCN, both of which directly bind to the mir-9-3 locus...
  16. doi Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bbeta and TSLC1 in neuroblastoma
    H Ochiai
    Division of Biochemistry and Molecular Carcinogenesis, Chiba Cancer Center Research Institute, Chiba, Japan
    Oncogene 29:2681-90. 2010
    ..In this paper, we clarified the direct binding of MYCN to Bmi1 promoter and upregulation of Bmi1 transcription by MYCN...
  17. doi MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response
    Marialaura Petroni
    Department of Experimental Medicine, Sapienza University of Rome, Policlinico Umberto I, Viale Regina Elena, 324, 00161, Rome, Italy
    Mol Cancer Res 9:67-77. 2011
    b>MYCN amplification occurs in approximately 20% of human neuroblastomas and is associated with early tumor progression and poor outcome, despite intensive multimodal treatment...
  18. pmc Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers
    Aslaug Helland
    Division of Surgery and Cancer, Department of Genetics, Institute for Cancer Research, Oslo University Hospital Radiumhospitalet, Oslo, Norway
    PLoS ONE 6:e18064. 2011
    ..DNA copy number and gene expression of HMGA2, alleles of Let-7, LIN28, LIN28B, MYC, MYCN, DICER1, and RNASEN were measured using microarray and quantitative reverse transcriptase PCR...
  19. doi Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma
    Alexander Schramm
    Department of Pediatric Hematology and Oncology, University Children s Hospital, Essen, Germany
    Int J Cancer 132:E106-15. 2013
    ..Neuroblastoma is a tumor of early childhood characterized by heterogeneous clinical courses. Amplification of the MYCN oncogene is a marker of poor patient outcome in this disease...
  20. pmc The histone deacetylase SIRT2 stabilizes Myc oncoproteins
    P Y Liu
    Children s Cancer Institute Australia for Medical Research, Randwick, Sydney, NSW 2031, Australia
    Cell Death Differ 20:503-14. 2013
    ..Our data reveal a novel pathway critical for Myc oncoprotein stability, and provide important evidences for potential application of SIRT2 inhibitors for the prevention and therapy of Myc-induced malignancies...
  21. ncbi Isolation and characterization of complementary DNA for N-cym, a gene encoded by the DNA strand opposite to N-myc
    B C Armstrong
    Department of Medicine, Medical College of Virginia, Richmond, Virginia
    Cell Growth Differ 3:385-90. 1992
    ..This coregulation suggests that their protein products may be functionally interrelated during normal development and oncogenesis...
  22. ncbi Sequence of a germ-line N-myc gene and amplification as a mechanism of activation
    J M Ibson
    Ludwig Institute for Cancer Research, Cambridge, UK
    Oncogene 2:399-402. 1988
    ....
  23. pmc Alternative processing of RNA transcribed from NMYC
    L W Stanton
    Department of Microbiology and Immunology, University of California Medical Center, San Francisco 94143
    Mol Cell Biol 7:4266-72. 1987
    b>NMYC is a gene whose amplification and overexpression have been implicated in the generation of certain human malignancies. Little is known of how the expression of NMYC is normally controlled...
  24. pmc Human proto-oncogene N-myc encodes nuclear proteins that bind DNA
    G Ramsay
    Mol Cell Biol 6:4450-7. 1986
    ..Our findings sustain the view that inordinate expression of N-myc may contribute to the genesis of several different human tumors...
  25. ncbi N-myc translation is initiated via an internal ribosome entry segment that displays enhanced activity in neuronal cells
    C L Jopling
    Department of Biochemistry, University of Leicester, University Road, Leicester LE1 7RH, UK
    Oncogene 20:2664-70. 2001
    ..The discovery of an IRES that displays enhanced activity in neuronal cell lines has important potential as a tool for protein expression in neural tissue...
  26. ncbi N-myc promotes survival and induces S-phase entry of postmitotic sympathetic neurons
    Kirmo Wartiovaara
    Brain Tumor Research Center and Center for Neuronal Survival, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada H3A 2B4
    J Neurosci 22:815-24. 2002
    ..Thus, N-myc both selectively causes sympathetic neurons to reenter the cell cycle and protects them from apoptosis, potentially contributing to their transformation to NBs...
  27. ncbi Quantification of MYCN, DDX1, and NAG gene copy number in neuroblastoma using a real-time quantitative PCR assay
    Katleen De Preter
    Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
    Mod Pathol 15:159-66. 2002
    Amplification of the proto-oncogene MYCN is a strong adverse prognostic factor in neuroblastoma patients in all tumor stages...
  28. ncbi Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma
    Jason M Shohet
    Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
    Cancer Res 62:1123-8. 2002
    The MYCN oncogene is amplified in approximately 25% of neuroblastoma tumors and is the most significant negative prognostic factor. The direct transcriptional targets of MYCN in MYCN-amplified tumors have not been defined...
  29. ncbi N-myc oncogene overexpression down-regulates leukemia inhibitory factor in neuroblastoma
    Elissavet Hatzi
    Laboratory of Biological Chemistry, Medical School, University of Ioannina, Greece
    Eur J Biochem 269:3732-41. 2002
    ..Our data shed light on the mechanisms by which N-myc oncogene amplification enhances the malignant phenotype in neuroblastoma...
  30. ncbi E2F proteins regulate MYCN expression in neuroblastomas
    Verena Strieder
    Institute of Molecular Biology and Tumor Research IMT, Emil Mannkopff Strasse 2, 35033 Marburg, Germany
    J Biol Chem 278:2983-9. 2003
    Amplification of the MYCN gene, resulting in overexpression of MYCN, distinguishes a subset of neuroblastomas with poor prognosis. The transcription factors driving MYCN expression in neuroblastomas are unknown...
  31. ncbi Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma
    Miguel Alaminos
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Res 63:4538-46. 2003
    Molecular mechanisms through which MYCN expression contributes to the malignant phenotype of neuroblastoma are unknown...
  32. pmc Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification
    Loen M Hansford
    Children s Cancer Institute Australia for Medical Research, Randwick 2031, Australia
    Proc Natl Acad Sci U S A 101:12664-9. 2004
    ..One tumorigenic factor in the embryonal childhood tumor neuroblastoma is the MYCN protooncogene...
  33. ncbi Investigation of MYCN status in neuroblastoma by fluorescence in situ hybridization
    Thomas S K Wan
    Department of Pathology, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, P R China
    Int J Mol Med 14:981-7. 2004
    ..We investigated 12 neuroblastoma patients for MYCN amplification and chromosome 2 aneusomy by fluorescence in situ hybridization (FISH) and results were correlated ..
  34. ncbi Linking of N-Myc to death receptor machinery in neuroblastoma cells
    Hongjuan Cui
    Department of Biochemistry and Cancer Biology, Medical College of Ohio, Toledo, Ohio 43614, USA
    J Biol Chem 280:9474-81. 2005
    The oncogene MYCN is amplified in aggressive neuroblastomas in which caspase-8, an essential component of death receptor pathways, is frequently inactivated, suggesting a critical role of death receptor-mediated apoptosis in suppression ..
  35. ncbi Inhibition of a new differentiation pathway in neuroblastoma by copy number defects of N-myc, Cdc42, and nm23 genes
    Linda J Valentijn
    Department of Human Genetics M1 134, Academic Medical Center, University of Amsterdam, P O Box 22700, 1100 DE Amsterdam, The Netherlands
    Cancer Res 65:3136-45. 2005
    ..Three regions of chromosomal gain and loss thus affect genes functioning in one pathway in neuroblastoma. They converge to bring the pathway out of balance and prevent Cdc42 mediated differentiation...
  36. ncbi Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma
    Anu Gupta
    Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA
    Cancer Res 66:8100-8. 2006
    Neuroblastoma is a heterogeneous disease in which 22% of tumors show MycN oncogene amplification and are associated with poor clinical outcome...
  37. pmc Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma
    Louis Chesler
    Department of Neurology, Comprehensive Cancer Center, University of California at San Francisco, San Francisco, CA 94143, USA
    Cancer Res 66:8139-46. 2006
    Amplification of MYCN occurs commonly in neuroblastoma...
  38. ncbi Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study
    Lisa A Moreau
    The National Center for Pediatric Cancer Genetics, Children s Oncology Group, University of Florida, Gainesville, FL, USA
    Clin Cancer Res 12:5693-7. 2006
    b>MYCN amplification in neuroblastoma tumor cells is manifested primarily as double minutes (dmins), whereas in cell lines it often appears in the form of homogeneously staining regions (HSR), suggesting that HSRs are associated with a more ..
  39. ncbi N-MYC regulates focal adhesion kinase expression in human neuroblastoma
    Elizabeth A Beierle
    Department of Surgery, University of Florida, Gainesville, Florida 32610, USA
    J Biol Chem 282:12503-16. 2007
    ..The results indicate that N-MYC regulation of FAK expression can control cellular functions in isogenic N-MYC(-/+) (Tet(+/-)) neuroblastoma cell lines...
  40. ncbi Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation
    Arjen Koppen
    Department of Human Genetics, Academic Medical Center, University of Amsterdam, P O Box 22700, 1100 DE Amsterdam, The Netherlands
    Cancer Lett 256:218-28. 2007
    ..Twenty percent of neuroblastomas show amplification of the MYCN oncogene, which correlates with poor prognosis...
  41. pmc Genes proximal and distal to MYCN are highly expressed in human neuroblastoma as visualized by comparative expressed sequence hybridization
    Cornelia Stock
    Children s Cancer Research Institute, St Anna Kinderkrebsforschung, Kinderspitalgasse 6, A 1090 Vienna, Austria
    Am J Pathol 172:203-14. 2008
    b>MYCN amplification is associated with poor prognosis in neuroblastoma disease...
  42. pmc N-myc coordinates retinal growth with eye size during mouse development
    Rodrigo A P Martins
    Department of Developmental Neurobiology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Genes Dev 22:179-93. 2008
    ..We propose that N-myc lies upstream of the cell cycle machinery in the developing mouse retina and thus coordinates the growth of both the retina and eye through extrinsic cues...
  43. pmc The MYCN oncogene is a direct target of miR-34a
    J S Wei
    Oncogenomics Section, Pediatric Oncology Branch, Advanced Technology Center, National Cancer Institute, Gaithersburg, MD 20892, USA
    Oncogene 27:5204-13. 2008
    Loss of 1p36 heterozygosity commonly occurs with MYCN amplification in neuroblastoma tumors, and both are associated with an aggressive phenotype...
  44. pmc Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas
    Frank Westermann
    Department of Tumor Genetics, German Cancer Research Center, Im Neuenheimer Feld 280, Heidelberg, Germany
    Genome Biol 9:R150. 2008
    Amplified MYCN oncogene resulting in deregulated MYCN transcriptional activity is observed in 20% of neuroblastomas and identifies a highly aggressive subtype...
  45. pmc N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor
    Rebecca Cotterman
    Department of Cell Biology, University of California Davis School of Medicine, Davis, California 95616, USA
    Cancer Res 68:9654-62. 2008
    ..These findings support a new dual model for Myc chromatin function with important implications for the role of Myc in cancer and stem cell biology, including that of induced pluripotent stem cells...
  46. doi Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma
    Tobias Otto
    Institute of Molecular Biology and Tumor Research, Marburg, Germany
    Cancer Cell 15:67-78. 2009
    In human neuroblastoma, amplification of the MYCN gene predicts poor prognosis and resistance to therapy...
  47. pmc Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas
    Olesya Chayka
    Molecular Haematology and Cancer Biology Unit, UCL Institute of Child Health, 30 Guilford St, London WC1N 1EH, UK
    J Natl Cancer Inst 101:663-77. 2009
    ..We investigated the role of clusterin in tumor development in mouse models of neuroblastoma...
  48. pmc N-Myc regulates expression of pluripotency genes in neuroblastoma including lif, klf2, klf4, and lin28b
    Rebecca Cotterman
    Department of Cell Biology and Human Anatomy, and Stem Cell Program, University of California Davis School of Medicine, Shriners Hospital for Children Northern California, Sacramento, California, USA
    PLoS ONE 4:e5799. 2009
    ..They also suggest mechanisms by which Myc proteins more generally contribute to maintenance of pluripotency and self-renewal of ESC as well as to iPSC formation...
  49. pmc Regulation of MYCN expression in human neuroblastoma cells
    Joannes F M Jacobs
    Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Donders Institute for Brain, Cognition and Behaviour, P O Box 9101, 6500 HB Nijmegen, The Netherlands
    BMC Cancer 9:239. 2009
    Amplification of the MYCN gene in neuroblastoma (NB) is associated with a poor prognosis. However, MYCN-amplification does not automatically result in higher expression of MYCN in children with NB...
  50. pmc Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo
    Zaowen Chen
    Texas Children s Cancer Center and Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
    Neoplasia 11:753-62. 2009
    ..Amplification of the MYCN oncogene correlates with the most clinically aggressive form of the cancer, and MDM2, a primary inhibitor of the ..
  51. doi Positive auto-regulation of MYCN in human neuroblastoma
    Yusuke Suenaga
    Division of Biochemistry and Innovative Cancer Therapeutics, Chiba Cancer Center Research Institute, Nitona, Chiba 260 8717, Japan
    Biochem Biophys Res Commun 390:21-6. 2009
    b>MYCN oncogene is one of the most important regulators affecting the prognosis of neuroblastoma and is frequently amplified in the high-risk subsets...
  52. doi MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors
    P Mestdagh
    Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
    Oncogene 29:1394-404. 2010
    ..Using neuroblastoma as a tumor model, we established a microRNA (miRNA) signature for activated MYCN/c-MYC signaling in two independent primary neuroblastoma tumor cohorts and provide evidence that c-MYC and MYCN ..
  53. pmc Global MYCN transcription factor binding analysis in neuroblastoma reveals association with distinct E-box motifs and regions of DNA hypermethylation
    Derek M Murphy
    Department of Cancer Genetics, Royal College of Surgeons in Ireland, Dublin, Ireland
    PLoS ONE 4:e8154. 2009
    ..The single most important prognostic indicator of poor clinical outcome in this disease is genomic amplification of MYCN, a member of a family of oncogenic transcription factors.
  54. pmc Opposing effects of two tissue transglutaminase protein isoforms in neuroblastoma cell differentiation
    Andrew E L Tee
    Children s Cancer Institute Australia, Sydney Children s Hospital, Sydney, New South Wales 2031, Australia
    J Biol Chem 285:3561-7. 2010
    ....
  55. pmc MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma
    Jakob Lovén
    Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, SE 171 77 Stockholm, Sweden
    Proc Natl Acad Sci U S A 107:1553-8. 2010
    b>MYCN, a proto-oncogene normally expressed in the migrating neural crest, is in its amplified state a key factor in the genesis of human neuroblastoma (NB)...
  56. pmc p53 is a direct transcriptional target of MYCN in neuroblastoma
    Lindi Chen
    Northern Institute for Cancer Research, Newcastle University, Department of Cellular Pathology, Royal Victoria Infirmary, Newcastle upon Tyne NE2 4H, United Kingdom
    Cancer Res 70:1377-88. 2010
    b>MYCN amplification occurs in approximately 25% of neuroblastomas, where it is associated with rapid tumor progression and poor prognosis. MYCN plays a paradoxical role in driving cellular proliferation and inducing apoptosis...
  57. pmc 2p24 Gain region harboring MYCN gene compared with MYCN amplified and nonamplified neuroblastoma: biological and clinical characteristics
    Marta Jeison
    Ca Cytogenetic Lab, Schneider Children s Medical Center of Israel, Kaplan St 14, 49202 Petah Tikva, Israel
    Am J Pathol 176:2616-25. 2010
    Although the role of MYCN amplification in neuroblastoma is well established, the biological and clinical characteristics of the 2p gain region harboring the MYCN gene remain unclear...
  58. pmc Pleiotropic role for MYCN in medulloblastoma
    Fredrik J Swartling
    University of California at San Francisco, San Francisco, California 94158, USA
    Genes Dev 24:1059-72. 2010
    ..To identify common signaling abnormalities, we profiled mRNA, demonstrating misexpression of MYCN in the majority of human MB and negligible expression in normal cerebella...
  59. doi Transcriptional upregulation of histone deacetylase 2 promotes Myc-induced oncogenic effects
    G M Marshall
    Children s Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, University of New South Wales, Sydney, New South Wales, Australia
    Oncogene 29:5957-68. 2010
    ....
  60. doi Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification
    Sara De Brouwer
    Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
    Clin Cancer Res 16:4353-62. 2010
    ..We carried out a meta-analysis of 709 neuroblastoma tumors to determine their frequency and mutation spectrum in relation to genomic and clinical parameters, and studied the prognostic significance of ALK copy number and expression...
  61. doi The FRA2C common fragile site maps to the borders of MYCN amplicons in neuroblastoma and is associated with gross chromosomal rearrangements in different cancers
    Anne Blumrich
    Department of Tumor Genetics, German Cancer Research Center DKFZ, Heidelberg 69121, Germany
    Hum Mol Genet 20:1488-501. 2011
    ..3 and 2p24.2, respectively. Both cFS are separated by a 2.8 Mb non-fragile region containing MYCN. Fine-tiling array comparative genomic hybridization of MYCN amplicons from neuroblastoma (NB) cell lines and ..
  62. pmc Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop
    Francesco Gualdrini
    Molecular Haeamatology and Cancer Biology Unit, UCL Institute of Child Health, London, UK
    Oncotarget 1:278-88. 2010
    b>MYCN is a member of the MYC family of oncoproteins frequently amplified or overexpressed in aggressive, paediatric tumours of the nervous system...
  63. doi MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma
    Bjørn Helge Haug
    Department of Pediatrics, University Hospital of North Norway, NO 9038 Tromsø, Norway
    Carcinogenesis 32:1005-12. 2011
    The MYCN oncogene is frequently amplified in neuroblastoma. It is one of the most consistent markers of bad prognosis for this disease. Dickkopf-3 (DKK3) is a secreted protein of the DKK family of Wnt regulators...
  64. pmc SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability
    Glenn M Marshall
    Children s Cancer Institute Australia for Medical Research, Randwick, Australia
    PLoS Genet 7:e1002135. 2011
    ..in pre-cancerous cells, and preventative treatment with the SIRT1 inhibitor Cambinol reduced tumorigenesis in TH-MYCN transgenic mice...
  65. pmc MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63
    L D Gamble
    Newcastle Cancer Centre at the Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
    Oncogene 31:752-63. 2012
    b>MYCN amplification is a major biomarker of poor prognosis, occurring in 25-30% of neuroblastomas. MYCN has contradictory roles in promoting cell growth and sensitizing cells to apoptosis...
  66. doi MYCN amplicon junctions as tumor-specific targets for minimal residual disease detection in neuroblastoma
    Hanna Kryh
    Department of Clinical Genetics, Institute of Biomedicine, The Sahlgrenska Academy at the University of Gothenburg, SE 41345 Gothenburg, Sweden
    Int J Oncol 39:1063-71. 2011
    The MYCN gene is frequently amplified in unfavorable neuroblastoma tumors...
  67. doi Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas
    Annelies Fieuw
    Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
    Int J Cancer 130:2599-606. 2012
    ..The majority of all detected 1q deletions was found in high risk 11q deleted tumors without MYCN amplification (Fisher exact test p = 5.61 × 10(-5) )...
  68. pmc MDM2 regulates MYCN mRNA stabilization and translation in human neuroblastoma cells
    L Gu
    Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA
    Oncogene 31:1342-53. 2012
    The MYCN gene has a critical role in determining the clinical behavior of neuroblastoma...
  69. pmc MYCN and MYC regulate tumor proliferation and tumorigenesis directly through BMI1 in human neuroblastomas
    Ruimin Huang
    Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, USA
    FASEB J 25:4138-49. 2011
    ..Using microarray and immunohistochemical analysis, we show that BMI1 expression correlated with MYCN levels in MYCN-amplified human neuroblastomas, and with MYC levels in the MYCN-nonamplified group...
  70. doi Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma
    Jesmin Akter
    Division of Biochemistry and Innovative Cancer Therapeutics, Chiba Cancer Center, Chiba, Japan
    Clin Cancer Res 17:6681-92. 2011
    ..However, the molecular mechanism of transcriptional regulation of NLRR3 remains elusive. This study was undertaken to clarify the transcriptional regulation of NLRR3 and its association with the prognosis of NBL...
  71. pmc Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study)
    G Schleiermacher
    INSERM U830, Laboratoire de Génétique et Biologie des Cancers, 26 Rue d Ulm, Paris Cedex 05, France
    Br J Cancer 105:1940-8. 2011
    ..In neuroblastoma (NB), the presence of segmental chromosome alterations (SCAs) is associated with a higher risk of relapse...
  72. pmc Activated ALK collaborates with MYCN in neuroblastoma pathogenesis
    Shizhen Zhu
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Cancer Cell 21:362-73. 2012
    Amplification of the MYCN oncogene in childhood neuroblastoma is often accompanied by mutational activation of ALK (anaplastic lymphoma kinase), suggesting their pathogenic cooperation...
  73. doi LIN28B induces neuroblastoma and enhances MYCN levels via let-7 suppression
    Jan J Molenaar
    Department of Oncogenomics, Academic Medical Center, Amsterdam, The Netherlands
    Nat Genet 44:1199-206. 2012
    ..LIN28B signaled through repression of the let-7 miRNAs and consequently resulted in elevated MYCN protein expression in neuroblastoma cells...
  74. pmc Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification
    Linda J Valentijn
    Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands
    Proc Natl Acad Sci U S A 109:19190-5. 2012
    Neuroblastoma is a pediatric tumor of the sympathetic nervous system. MYCN (V-myc myelocytomatosis viral-related oncogene, neuroblastoma derived [avian]) is amplified in 20% of neuroblastomas, and these tumors carry a poor prognosis...
  75. pmc Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications
    Daisy Corvetta
    Molecular Haematology and Cancer Biology Unit, University College London Institute of Child Health, London WC1N 1EH, United Kingdom
    J Biol Chem 288:8332-41. 2013
    CLU (clusterin) is a tumor suppressor gene that we have previously shown to be negatively modulated by the MYCN proto-oncogene, but the mechanism of repression was unclear...
  76. pmc Targeting MYCN in neuroblastoma by BET bromodomain inhibition
    Alexandre Puissant
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02215, USA
    Cancer Discov 3:308-23. 2013
    ..Integration of genetic features with chemosensitivity data revealed a robust correlation between MYCN amplification and sensitivity to bromodomain inhibition...
  77. pmc Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma
    Markus Brockmann
    Comprehensive Cancer Center Mainfranken and Theodor Boveri Institute, Biocenter, University of Wurzburg, Am Hubland, 97074 Wurzburg, Germany
    Cancer Cell 24:75-89. 2013
    Amplification of MYCN is a driver mutation in a subset of human neuroendocrine tumors, including neuroblastoma. No small molecules that target N-Myc, the protein encoded by MYCN, are clinically available...
  78. pmc S(+)-ibuprofen destabilizes MYC/MYCN and AKT, increases p53 expression, and induces unfolded protein response and favorable phenotype in neuroblastoma cell lines
    Naohiko Ikegaki
    Department of Anatomy and Cell Biology, College of Medicine, University of Illinois at Chicago, Chicago, IL, USA
    Int J Oncol 44:35-43. 2014
    ..The survival rate of children with unfavorable neuroblastoma remains low among all childhood cancers. MYCN and MYC play a crucial role in determining the malignancy of unfavorable neuroblastomas, whereas high-level ..
  79. pmc Drugging MYCN through an allosteric transition in Aurora kinase A
    William Clay Gustafson
    Department of Pediatrics, UCSF Benioff Children s Hospital, University of California, San Francisco, San Francisco, CA 94158, USA Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA
    Cancer Cell 26:414-27. 2014
    ..Proteolytic degradation of MYCN protein is regulated in part by a kinase-independent function of Aurora A...
  80. pmc Nucleotide sequence of the human N-myc gene
    L W Stanton
    Proc Natl Acad Sci U S A 83:1772-6. 1986
    ..The resemblance between the proteins encoded by N-myc and c-myc sustains previous suspicions that the genes encode related functions...
  81. ncbi Concomitant DDX1 and MYCN gain in neuroblastoma
    Raffaella Defferrari
    Laboratory of Neuroblastoma Research, Italian Neuroblastoma Foundation, National Institute for Cancer Research IST, Largo R Benzi 10, 16132 Genoa, Italy
    Cancer Lett 256:56-63. 2007
    DDX1, a gene mapping to the 2p24 region, has been observed to be co-amplified with MYCN in neuroblastoma. Co-amplification of the DDX1 gene is a consequence of the short physical distance between the two genes...
  82. ncbi p14ARF interacts with N-Myc and inhibits its transcriptional activity
    Stefano Amente
    Department of Structural and Functional Biology, University of Naples Federico II, Naples, Italy
    FEBS Lett 581:821-5. 2007
    ..Finally, we determine that the N-terminal region of the p14(ARF) protein is involved in binding to c-Myc and N-Myc proteins...
  83. ncbi Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc
    M Schwab
    Nature 308:288-91. 1984
    ....
  84. doi Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group
    Jennifer Schneiderman
    Children s Memorial Hospital, Department of Pediatrics, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA
    J Clin Oncol 26:913-8. 2008
    b>MYCN amplification is rarely detected in patients with favorable-stage neuroblastoma (NB)...
  85. ncbi The homeobox gene MEIS1 is amplified in IMR-32 and highly expressed in other neuroblastoma cell lines
    T A Jones
    Human Cytogenetics Laboratory, Imperial Cancer Research Fund, Lincoln's Inn Fields, London, UK
    Eur J Cancer 36:2368-74. 2000
    ..High expression of MEIS1 without amplification was also found in other neuroblastoma cell lines, with and without MYCN amplification, and in medulloblastoma and crythroleukaemia cell lines...
  86. ncbi N-myc and c-myc oncogenes amplification in medulloblastomas. Evidence of particularly aggressive behavior of a tumor with c-myc amplification
    M Badiali
    Department of Pediatrics, University of Bologna, Italy
    Tumori 77:118-21. 1991
    ..Medulloblastomas with c-myc activation may represent a subgroup of tumors with a more aggressive behavior...
  87. pmc Fluorescence in situ hybridization techniques for the rapid detection of genetic prognostic factors in neuroblastoma. United Kingdom Children's Cancer Study Group
    C P Taylor
    Human Cytogenetics Laboratory, Imperial Cancer Research Fund, Lincoln s Inn Fields, London, UK
    Br J Cancer 83:40-9. 2000
    ..powerful biological parameters associated with prognosis in this malignancy are chromosomal changes, especially MYCN amplification, deletion of chromosome 1p and aneuploidy...
  88. pmc Rapid detection of prognostic genetic factors in neuroblastoma using fluorescence in situ hybridisation on tumour imprints and bone marrow smears. United Kingdom Children's Cancer Study Group
    C P Taylor
    Human Cytogenetics Laboratory, Imperial Cancer Research Fund, London, UK
    Br J Cancer 69:445-51. 1994
    ....
  89. pmc Mutations in PIK3CA are infrequent in neuroblastoma
    Vincent Dam
    Division of Oncology, The Children s Hospital of Philadelphia Philadelphia, PA, USA
    BMC Cancer 6:177. 2006
    Neuroblastoma is a frequently lethal pediatric cancer in which MYCN genomic amplification is highly correlated with aggressive disease...
  90. doi Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience
    Adela Canete
    Unidad de Oncología Pediátrica, Hospital Infantil La Fe, Avda de Campanar 21, 46009 Valencia, Spain
    J Clin Oncol 27:1014-9. 2009
    To report the results of a prospective, nonrandomized European study on infants with neuroblastoma and MYCN gene amplification.
  91. ncbi [Detection of n-myc gene amplification in neuroblastoma using polymerase chain reaction based methods]
    Zsombor Melegh
    Molekuláris Pathologiai Osztály, Országos Onkológiai Intézet, Budapest, H1122, Hungary
    Magy Onkol 46:43-8. 2002
    ..We used biotinylated ATP labelling and the same primer pair as for the LightCycler analysis.In both cases differentiated cell forms did not show n-myc gene amplification, while considerable amplification was detected in the neuroblasts...
  92. doi Microgravity assay of neuroblastoma: in vitro aggregation kinetics and organoid morphology correlate with MYCN expression
    Robert A Redden
    Center for Fetal Research, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    In Vitro Cell Dev Biol Anim 47:312-7. 2011
    ..Specifically, we examined the effect of amplification of the oncogene MYCN, a genetic factor that is strongly associated with poor clinical outcome...
  93. pmc Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2(SSTR2) gene at 17q24
    F Abel
    Department of Clinical Genetics Sahlgrenska University East, Gothenburg, Sweden
    Br J Cancer 81:1402-9. 1999
    Deletion of chromosome arm 1p and amplification of the MYCN oncogene are well-recognized genetic alterations in neuroblastoma cells. Recently, another alteration has been reported; gain of the distal part of chromosome arm 17q...
  94. ncbi N-Myc and Bcl-2 coexpression induces MMP-2 secretion and activation in human neuroblastoma cells
    Daniel Noujaim
    Department of Neurology, University of Michigan, Ann Arbor 48109, USA
    Oncogene 21:4549-57. 2002
    ..These data imply that N-Myc and Bcl-2 cooperate to increase the expression, secretion, and activation of MMP-2, which likely leads to a more tumorigenic phenotype due to increased MMP-2 mediated invasion...
  95. pmc MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2
    Niamh H Foley
    Department of Cancer Genetics, Royal College of Surgeons in Ireland, York House, York Street, Dublin 2, Ireland
    Mol Cancer 9:83. 2010
    ..The single most important genetic indicator of poor clinical outcome is amplification of the MYCN transcription factor...
  96. pmc Allelic imbalance on chromosome 5q predicts long-term survival in neuroblastoma
    S J Meltzer
    Department of Medicine, University of Maryland, Baltimore 21201, USA
    Br J Cancer 74:1855-61. 1996
    ..These data suggest that allelic imbalance of chromosome 5 is involved in at least a subset of neuroblastomas and influences survival in patients with neuroblastoma...
  97. ncbi Surgery in pediatric solid tumors with special reference to advanced neuroblastoma
    Yoshiaki Tsuchida
    Department of Surgery, Gunma Children s Medical Center, Seta gun, Japan
    Acta Paediatr Taiwan 43:67-71. 2002
    The role of surgery in Wilms' tumor and hepatoblastoma is well established, but that in advanced neuroblastoma is controversial. We analyzed factors contributing to the long-term survival of patients with MYCN-amplified neuroblastoma.
  98. pmc Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database
    Rochelle Bagatell
    University of Arizona Health Sciences Center, Tucson, AZ, USA
    J Clin Oncol 27:365-70. 2009
    ..To evaluate the outcome of children with low-stage MYCN-amplified neuroblastoma and develop a rational treatment strategy, data from the International Neuroblastoma Risk ..
  99. ncbi Biological characteristics of neuroblastoma with partial deletion in the short arm of chromosome 1
    E Hiyama
    Department of General Medicine, Hiroshima University School of Medicine, Japan
    Med Pediatr Oncol 36:67-74. 2001
    ..It is well known that almost all cases with MYCN amplification have a poor prognosis...
  100. ncbi The neuroblastoma amplified gene, NAG: genomic structure and characterisation of the 7.3 kb transcript predominantly expressed in neuroblastoma
    D K Scott
    Cancer Research Unit, Northern Institute of Cancer Research, University of Newcastle Medical School, Framlington Place, Newcastle upon Tyne NE2 4HH, UK
    Gene 307:1-11. 2003
    Amplification of the MYCN oncogene in neuroblastoma is associated with poor prognosis. The amplified unit of DNA can be up to 1 Mb in size and so could contain additional genes which affect tumour phenotype...
  101. ncbi Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma
    Ruediger Spitz
    University of Cologne, Children s Hospital, Pediatric Oncology, 50924 Köln, Germany
    Clin Cancer Res 9:4835-40. 2003
    ..long arm of chromosome 17 was shown to be a frequent and prognostically relevant factor in neuroblastoma, in addition to MYCN amplification (MNA) or 1p deletion. We asked whether this observation could be confirmed in a German cohort.

Research Grants62

  1. N-myc Targeted Therapeutics for Childhood Neuroblastoma
    CATHERINE BURKHART; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  2. NF-kappaB N-myc in Oncogenic Pathways of the CNS
    Raquel Sitcheran; Fiscal Year: 2010
    ..to evaluate the biological significance of the interaction between NF-KB and N-myc and the mechanism by which Nmyc represses NF-KB...
  3. ANTIBODIES TO INVESTIGATE AND TREAT NEUROBLASTOMA
    Christopher Frantz; Fiscal Year: 1992
    ..The proposed investigations will define the role of the N-myc oncogene in the growth, differentiation and metastasis of neuroblastoma...
  4. Role of Polyamines in MYCN-Amplified Neuroblastoma
    ANDRE BACHMANN; Fiscal Year: 2009
    ..One of the most striking abnormalities found in NB tumors is the amplification of the MYCN oncogene, which strongly correlates with more aggressive tumors and poor prognosis of late stage disease...
  5. Genetic Susceptibility Factors in the Etiology of Neuroblastoma
    Andrew Olshan; Fiscal Year: 2012
    ..evaluate genetic effects within NB subgroups defined by age at diagnosis and a classification schema based on age, MYCN oncogene status, histology, and DNA ploidy...
  6. Development of sd-rxRNAs as Therapy for Retinoblastoma and Other Malignancies
    Pamela Pavco; Fiscal Year: 2012
    ..extremely high expression of murine double minute oncogene (MDM2), V-myc myelocytomatosis viral related oncogene (MYCN), thyroid hormone receptor [unreadable]2 (THRB2) and retinoic acid receptor gamma (RXRG) nuclear receptor...
  7. DANA LYNN TAKEKO KOOMOA; Fiscal Year: 2016
    ..Amplification of the proto-oncogene MYCN is associated with advanced stage, high risk NB and poor prognosis...
  8. Min Hee Kang; Fiscal Year: 2016
    ..RA is as active as the parent drug in activation of retinoid signaling, inhibition of cell proliferation, and MYCN down-regulation in neuroblastoma cells...
  9. MYCN Function in Neuroblastoma
    Naohiko Ikegaki; Fiscal Year: 2012
    ..Twenty percent of NB cases have MYCN amplification, which is strongly associated with older age, advanced stage disease, rapid tumor progression, and ..
  10. Jianhua Yang; Fiscal Year: 2014
    ..The proposed experiments will test this hypothesis by using an orthotopic and TH-MYCN transgenic mouse models to analyze the effect of TAK1 inhibitor on tumor chemoresistance and tumor microenvironment...
  11. Modifiers of Tumor Susceptibility in Murine Neuroblastoma
    William A Weiss; Fiscal Year: 2012
    ..Amplification of the transcription factor MYCN occurs frequently in this tumor, and correlates with advanced disease...
  12. ELENA LEVITSKAIA; Fiscal Year: 2014
    ..Similar data were obtained using NB tumors spontaneously arising in transgenic TH- MYCN mice...
  13. Reverse ChIP: Sequence-specific extraction of DNA-bound histones for analysis of
    Johannes Dapprich; Fiscal Year: 2012
    ..modifications originating from specific disease- associated loci from tumor and normal biospecimens, such as the MYCN locus amplified in neuroblastoma...
  14. MOLECULAR GENETIC ANALYSIS OF HUMAN NEUROBLASTOMA
    Garrett M Brodeur; Fiscal Year: 2013
    ..We will also cross CHD5 KO mice with TH-MYCN transgenic mice to determine if NB tumorigenicity is accelerated...
  15. Linda H Shapiro; Fiscal Year: 2016
    ..alone and in combination with topoisomerse inhibitors across selected NB cell lines, xenografts and in the MYCN transgenic model...
  16. Hypoxia in neuroblastoma
    Guoliang Qing; Fiscal Year: 2010
    ..This research aims to identify novel therapeutic targets and is of great significance to public health. ..
  17. ROBERT CHARLES SEEGER; Fiscal Year: 2014
    ..including PI3K, PI3K+mT0R, and Aurora Kinase A inhibitors that result in destabilization and degradation [sic] the MYCN protein, are investigated for their anti-tumor cell activity as well as their effects upon microenvironment cells...
  18. Translational Genomics of MicroRNAs in Neuroblastoma
    KRISTINA ANN COLE; Fiscal Year: 2013
    ..years of knowledge of recurrent genomic abnormalities in neuroblastoma, other than the neuroblastoma oncogene MYCN, the gene targets of these aberrations has remained unknown, and no bona-fide neuroblastoma tumor suppressor genes ..
  19. The oncogenic basis of Bmi-1 in neuroblastoma development
    Han Fei Ding; Fiscal Year: 2010
    ..We will examine the effects Bmi-1 deficiency on neuroblastoma initiation and progression in MYCN mice, an animal model of the human disease...
  20. The Role of Caspase-8 in Neuroblastoma Tumorigenesis
    GERARD PAUL ZAMBETTI; Fiscal Year: 2013
    ..and that modulation of caspase-8 expression and/or activity cooperate with other genetic changes, such as MYCN over-expression in tumor formation. To test this hypothesis we plan to: 1...
  21. Shizhen Zhu; Fiscal Year: 2014
    ..I recently demonstrated that activated ALK synergizes with MYCN to induce neuroblastoma in zebrafish by inhibiting a developmentally-timed apoptotic response (Zhu et al, Cancer ..
  22. Gene Expression of Neuroblastoma and Normal Cells in Bone Marrow Predicts Outcome
    ROBERT CHARLES SEEGER; Fiscal Year: 2012
    ..project, we have developed another TLDA assay that quantifies a prognostic 14-gene expression signature in primary MYCN non-amplified tumors to predict outcome, and another signature is being developed for MYCN amplified tumors...
  23. VEGF blockade and alternative angiogenic pathways in neuroblastoma
    Darrell J Yamashiro; Fiscal Year: 2012
    ..well-characterized xenograft model, in which NB cell lines are implanted in the kidney of athymic mice, and the TH-MYCN genetic model of NB, we will, in Aim 1, determine whether VEGFR1 signaling can rescue tumor vasculature from VEGFR2 ..
  24. MiRNA Expression in Neuroblastoma
    RAYMOND LOUIS STALLINGS; Fiscal Year: 2012
    ..effects of forced over or under-expression of miRNA loci in NBL cell lines;4) validate miRNAs that target MYCN or upstream regulators of MYCN, allowing us to identify naturally occurring miRNAs capable of suppressing MYCN ..
  25. Discovery of Chromosome Arm 11q Tumor Suppressor Genes in Neuroblastoma
    Edward F Attiyeh; Fiscal Year: 2010
    ..Most invasive neuroblastomas are defined either by MYCN amplification (40%) or 11q loss of heterozygosity (30%), but rarely do these occur in the same tumor...
  26. William A Weiss; Fiscal Year: 2016
    DESCRIPTION (provided by applicant): Neuroblastoma is a common and lethal tumor of childhood. Amplification of MYCN occurs commonly in high-risk disease...
  27. CLINICAL CORRELATIVE STUDIES OF NEUROBLASTOMA
    ROBERT CHARLES SEEGER; Fiscal Year: 2010
    ..We discovered a 55 gene signature from expression profiles of MYCN gene non-amplified tumors that identifies patients with 79% and 16% PFS...
  28. The Role of Caspase-8 in Neuroblastoma Tumorigenesis
    Jill Lahti; Fiscal Year: 2009
    ..role of caspase-8 in NB cell metastasis 2) determine the consequences of CASP8 silencing in relationship to MYCN amplification/overexpression and 1p36 LOH in neuroblastoma, and 3) determine the combined effects(s) of these ..
  29. William Clay Gustafson; Fiscal Year: 2014
    ..Amplification of MYCN, a MYC family ontogeny, occurs in ~25% of neuroblastoma and marks high-risk disease...
  30. Focal Adhesion Kinase (FAK) in Human Neuroblastoma
    Elizabeth A Beierle; Fiscal Year: 2011
    ..This proposal builds upon preliminary data demonstrating a correlation between FAK expression and MYCN oncogene amplification, and the effects of attenuation of FAK upon cellular survival...
  31. HUMAN NEUROBLASTOMA ANTIGENS
    Robert Seeger; Fiscal Year: 2000
    ..Their previous research suggests that the proto-oncogene MYCN, the neurotrophin receptors TrkA and p75TNR, and the neurotrophin Nerve Growth Factor (NGF) have important roles in ..
  32. Role of Ceramide in Human Neuroblastoma Differentiation
    JACQUELINE KRAVEKA; Fiscal Year: 2007
    ..Increased telomerase activity is emerging as a prognostic factor in neuroblastoma, associated with advanced stage, MYCN amplification and poor outcome...
  33. GENOMICS OF HUMAN NEUROBLASTOMA
    Yael Mosse; Fiscal Year: 2009
    ..rearrangements and can be subdivided into two major subsets: 1p deletion and high-level amplification of the MYCN oncogene in the most aggressive subset (40% of high-risk cases), and unbalanced loss of 11q material and 3p LOH ..
  34. IMMUNOCYTOLOGY OF MARROW METASTASES IN NEUROBLASTOMA
    Robert Seeger; Fiscal Year: 1991
    ..We anticipate that these studies will contribute to a better understanding of neuroblastoma and to therapy that is more effective and specific...
  35. POST TRANSCRIPTIONAL CONTROL OF THE HUMAN N MYC GENE
    William Carroll; Fiscal Year: 2002
    ....
  36. FLUORESCENT TISH PROBES FOR CANCER REVELANT SEQUENCES
    JACQUES FRESCO; Fiscal Year: 2001
    ....
  37. FLUORESCENT TISH PROBES FOR CANCER REVELANT SEQUENCES
    JACQUES FRESCO; Fiscal Year: 2004
    ....
  38. Genetic variation and regulatory networks: Mechanisms and complexity
    DANA PE ER; Fiscal Year: 2009
    ..These tools will be made publicly available, including a friendly graphical user interface and visualization. ..
  39. TRANSCRIPTIONAL REPRESSION AND CELL CYCLE MECHANISMS
    Amy Yee; Fiscal Year: 2000
    ....
  40. REGULATION OF NEUROBLASTOMA DIFFERENTIATION IN CULTURE
    Emil Bogenmann; Fiscal Year: 1991
    ..We will attempt to study a link between mechanisms controlling development and genetic elements with transforming potential...
  41. INDUCTION OF HUMAN NEUROBLASTOMA DIFFERTIATION
    Charles Reynolds; Fiscal Year: 1990
    ..Methods developed for assessing neuroblastoma differentiation in vitro will be valuable in assessing the effects of differentiation inducers in vivo during clinical trials...
  42. REGULATION OF THE N-MYC ONCOGENE IN NEUROBLASTOMA
    RANDAL WADA; Fiscal Year: 2004
    ..Ultimately, an understanding of oncogene regulation will facilitate the future rational development of combination differentiation therapy of neuroblastoma, which might be effective even in the induction setting against bulky disease. ..
  43. INDUCED DIFFERENTIATION OF NEUROBLASTOMA
    Neil Sidell; Fiscal Year: 1999
    ..By understanding the relationship between RA, IFNg and NaPA in controlling nb differentiation, these studies will provide a basic framework for the expanded clinical use of retinoids in a multidrug setting. ..
  44. N-myc Targeted Therapeutics for Childhood Neuroblastoma
    CATHERINE BURKHART; Fiscal Year: 2004
    ..Completion of Phase II will identify those molecules that have the potential to be used clinically in neuroblastoma treatment regimens. ..
  45. ZD1839 Therapy of Glioblastoma Multiforme
    Henry Friedman; Fiscal Year: 2002
    ....
  46. Anthony E Oro; Fiscal Year: 2015
    ..Discovering genes that are directly regulated by Hh signaling will lead to new ways to intervene when errors in signal transduction lead to birth defects or cancer. ..
  47. The role of NDRG1 in collecting duct function.
    ANIKO NARAY FEJES TOTH; Fiscal Year: 2010
    ..Furthermore, we are trying to understand the mechanisms by which different steroid hormone receptors exert specific actions on the kidney. ..
  48. The Ureb-1 ubiquitin ligase in neural stem cells and cancer
    Anna Lasorella; Fiscal Year: 2012
    ..We have identified a new ubiquitin ligase for N-Myc in neural cells and will test whether defects in N-myc turnover affects neural stem cells and initiates cancer in the brain. ..
  49. Mycn and Medulloblastoma
    William A Weiss; Fiscal Year: 2013
    ..The proto-oncogene Mycn is the major factor driving proliferation in the developing cerebellum, and is expressed at high levels in SHH-..
  50. Nanovectors For Brain Tumor Diagnosis And Treatment
    Miqin Zhang; Fiscal Year: 2011
    ..siRNA delivery and subsequent suppression of the reporter gene in 9L/LacZ cells;and (3) deliver siRNA against Nmyc, a gene necessary for medulloblastoma proliferation, and evaluate the efficacy of nanovector-delivered Nmyc siRNA ..
  51. James A DeCaprio; Fiscal Year: 2016
    ..My laboratory identified LMyc, NMyc, Max as well as the entire, 15-component, Tip60/TRRAP complex in a large-scale immunoprecipitation for MCPyV ST ..
  52. William A Weiss; Fiscal Year: 2014
    ..We also propose additional SB based experiments to identify metastases genes in a novel MYCN-driven model for MB which arises largely independently of Shh signaling and which models both classic (60% of human ..
  53. DIANE LOUISE CARLISLE; Fiscal Year: 2015
    ..Effects of nicotine in vitro will be confirmed using a murine explant model of in vivo lung development. ..
  54. William A Weiss; Fiscal Year: 2016
    ..The transcription factors MYC and MYCN are expressed in the majority of these tumors, but are essentially untargetable...
  55. Rajeev S Samant; Fiscal Year: 2014
    ..Aim 4: To determine correlation between loss of Nmi expression and activated Wnt/[unreadable]-catenin signaling in patient derived breast cancer specimens. ..
  56. Justin Meyerowitz; Fiscal Year: 2015
    ..These subgroups are characterized by increased levels of transcription factors MYCN or MYC, as well as independence from sonic hedgehog (SHH) signaling...
  57. David MacPherson; Fiscal Year: 2014
    ..If pathways controlled by RB family members are functionally inactivated through secondary alterations, then reactivation of such pathways may provide new opportunities for therapeutic intervention. ..
  58. Neuroblastoma Tumor Suppressor Genes in Zebrafish
    A Look; Fiscal Year: 2007
    ..important in NB pathogenesis and normal PSNS development; and (ii) transgenic zebrafish overexpressing the human MYCN oncogene in the developing PSNS can be used to determine the role of MYCN amplification in aberrant sympathetic ..
  59. ELAV-LIKE PROTEINS IN NEUROBLASTOMA
    Susan Cohn; Fiscal Year: 2000
    ..Thus, ultimately, these studies may provide the clues necessary for the development of effective therapy for children with NB tumors that express high levels of N-myc and are clinically aggressive. ..
  60. Providers' perceptions of the diaphragm in Southern Afr*
    Cynthia Harper; Fiscal Year: 2005
    ..prevention, the diaphragm has been replaced by more effective hormonal methods and is often viewed as out-moded. If proven effective as a STI-prevention device, any successful reintroduction of the diaphragm will depend ..
  61. PATHWAY OF VENTRICULAR MORPHOGENESIS MEDICATED BY RXRA
    Henry Sucov; Fiscal Year: 2001
    ..abstract_text> ..
  62. IRSG LABORATORY CORRELATIVE STUDIES
    FREDERIC BARR; Fiscal Year: 1999
    ..In particular, mutations of p53 and RAS genes, amplification of MYCN and 12q13-15 loci, and deletions of CDKN2A have been reported in cases of RMS...